Analysts See $0.32 EPS for Qiagen NV (QGEN)

October 13, 2017 - By Kurt Siggers

 Analysts See $0.32 EPS for Qiagen NV (QGEN)

Investors wait Qiagen NV (NASDAQ:QGEN) to report on November, 1. its quarterly earnings Wall Street analysts expect $0.32 earnings per share, up $0.02 or 6.67 % from last year’s $0.3 same quarter earnings. This translates into $73.80M profit for QGEN giving the stock a 27.10 P/E. This is assuming the current $0.32 EPS is accurate. Qiagen NV’s Wall Street analysts see 6.67 % EPS growth, taking into account the $0.30 EPS reproted in the previous quarter, About 1.85 million shares traded or 20.13% up from the average. Qiagen NV (NASDAQ:QGEN) has risen 54.62% since October 13, 2016 and is uptrending. It has outperformed by 37.92% the S&P500.

Qiagen NV (NASDAQ:QGEN) Ratings Coverage

Among 13 analysts covering Qiagen (NASDAQ:QGEN), 4 have Buy rating, 0 Sell and 9 Hold. Therefore 31% are positive. Qiagen had 21 analyst reports since August 3, 2015 according to SRatingsIntel. The rating was upgraded by Independent Research on Tuesday, August 1 to “Hold”. The rating was initiated by Stifel Nicolaus with “Hold” on Thursday, November 12. The stock has “Hold” rating by Jefferies on Wednesday, September 13. The stock has “Hold” rating by Cowen & Co on Monday, August 14. Citigroup maintained Qiagen NV (NASDAQ:QGEN) rating on Tuesday, March 15. Citigroup has “Neutral” rating and $25 target. The stock of Qiagen NV (NASDAQ:QGEN) earned “Overweight” rating by Barclays Capital on Thursday, July 30. Mizuho maintained it with “Neutral” rating and $25 target in Thursday, July 30 report. The firm earned “Neutral” rating on Thursday, November 3 by Bank of America. The stock of Qiagen NV (NASDAQ:QGEN) has “Hold” rating given on Monday, June 5 by Jefferies. Piper Jaffray maintained the shares of QGEN in report on Friday, July 28 with “Hold” rating.

QIAGEN N.V. is a holding company. The company has market cap of $8.00 billion. The Firm is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. It has a 105.62 P/E ratio. The Company’s Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems.

Another recent and important Qiagen NV (NASDAQ:QGEN) news was published by Investorplace.com which published an article titled: “Qiagen NV (QGEN) Hold Recommendation Confirmed” on October 05, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.